Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

LEGEND BIOTECH CORPORATION

(LEGN)
  Rapport
Geschatte realtime Cboe BZX  -  18:14 30-11-2022
50.02 USD   +3.10%
22/11Genscript Biotech Unit krijgt goedkeuring van de Amerikaanse FDA voor de klinische ontwikkeling van een therapie tegen kleincellige longkanker.
MT
21/11Legend Biotech Corporation kondigt FDA goedkeuring aan van IND aanvraag voor LB2102 in uitgebreid stadium van kleincellige longkanker
CI
03/11Legend Biotech Corporation deelt bijgewerkte gegevens van uitgebreid klinisch ontwikkelingsprogramma Cilta-Cel op ASH 2022
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Dagen
:
Uren
:
Minuten
:
Seconden
Communiquťs de presse de la sociťtť LEGEND BIOTECH CORPORATION
22/11Legend Biotech : Extends Interim Product Supply Agreement with Janssen Pharmaceuticals, In..
PU
21/11Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage..
BU
07/11Legend Biotech Announces Participation in Upcoming Investor Conferences
AQ
04/11Legend Biotech Announces Participation in Upcoming Investor Conferences
BU
03/11Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Pr..
BU
20/10Legend Biotech : Non-Reliance on Previously Issued Financial Statements - Form 6-K
PU
17/10Legend Biotech : Voting Results of 2022 Annual General Meeting - Form 6-K
PU
13/10Legend Biotech : 2022 Annual General Meeting
PU
02/10Legend Biotech : Research and Development Day 2022
PU
28/09Legend Biotech - CARVYKTI Receives Approval from Japan's Ministry of Health, Labour and..
AQ
27/09CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan's Ministry of ..
BU
27/09Legend Biotech : CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan'..
PU
16/09Legend Biotech : PROXY STATEMENT - Form 6-K
PU
15/09Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022
BU
15/09Legend Biotech : to Host 2022 R&D Day on Monday, October 3, 2022
PU
19/08Legend Biotech : Announces Participation in Upcoming Investor Conferences - Form 6-K
PU
19/08Legend Biotech Announces Participation in Upcoming Investor Conferences
BU
05/08Legend Biotech : Announces Preliminary Results for the Six-Months Ended June 30, 2022 - Fo..
PU
05/08Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022
BU
04/08Legend Biotech : Appoints Three New Directors and Elects New Chairman of the Board - Form ..
PU
04/08Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board
BU
27/07Legend Biotech : Announces Pricing of Public Offering - Form 6-K
PU
27/07Legend Biotech Corporation Announces Pricing of Public Offering
BU
25/07Legend Biotech : Announces Proposed Public Offering - Form 6-K
PU
25/07Legend Biotech Corporation Announces Proposed Public Offering
BU
21/07Legend Biotech : Announces Preliminary Sales for CARVYKTI™ for the Quarter Ended Jun..
PU
13/07Legend Biotech : AMENDMENT NO. 1 TO INTERIM PRODUCT SUPPLY AGREEMENT - Form 6-K
PU
07/07Legend Biotech : Announces Termination of its Phase 1 Clinical Trial Under Investigational..
PU
06/06Legend Biotech : Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable..
PU
04/06Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses wit..
BU
03/06Legend Biotech : Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB..
PU
03/06Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, L..
BU
02/06Legend Biotech : to Host Investors at the 2022 American Society of Clinical Oncology (ASCO..
PU
01/06Legend Biotech : Reports First Quarter 2022 Financial Results and Recent Highlights - Form..
PU
01/06Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights
BU
31/05Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASC..
BU
26/05Legend Biotech : CARVYKTIģ (ciltacabtagene autoleucel) Granted Conditional Approval by the..
PU
26/05CARVYKTIģ (ciltacabtagene autoleucel) Granted Conditional Approval by the European Comm..
BU
18/05Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma Wit..
BU
09/05Legend Biotech Appoints Lori Macomber as Chief Financial Officer
BU
06/05Legend Biotech Announces Participation in Upcoming Investor Conferences
BU
21/04Legend Biotech : Achieves Milestone Under Collaboration Agreement with Janssen Biotech, In..
PU
01/04Legend Biotech : Announces Appointment of Global Head of Research and Early Development - ..
PU
01/04Legend Biotech Announces Appointment of Global Head of Research and Early Development
BU
25/03Legend Biotech : CARVYKTIģ (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for ..
PU
25/03CARVYKTIģ (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment ..
BU
23/03Flanders Investment and Trade Names Legend Biotech Newcomer of the Year
BU
18/03Legend Biotech : Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Hi..
PU
18/03Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent H..
BU
01/03Legend Biotech : CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy,..
PU
01/03CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S...
BU
18/02Legend Biotech : Announces Preliminary Results for the Year Ended December 31, 2021 - Form..
PU
18/02Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021
BU
15/02Legend Biotech : Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901 - Fo..
PU
15/02Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901
BU
11/02Legend Biotech : Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen - Fo..
PU
11/02Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen
BU
10/01Legend Biotech : 40th Annual J.P. Morgan Healthcare Conference
PU
04/01Legend Biotech : to Participate in the 40th Annual J.P. Morgan Healthcare Conference - For..
PU
04/01Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference
BU
2021Legend Biotech : Announces Appointment of Dr. Ying Huang to the Board of Directors - Form ..
PU
2021Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors
BU
2021Legend Biotech : Announces Pricing of Public Offering - Form 6-K
PU
2021Legend Biotech Corporation Announces Pricing of Public Offering
BU
2021Legend Biotech : Announces Proposed Public Offering - Form 6-K
PU
2021Legend Biotech : Announces Proposed Public Offering
PU
2021Legend Biotech : Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Respo..
PU
2021Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltac..
BU
2021Legend Biotech : ASH 2021 Investor Meeting
PU
2021Legend Biotech : to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63rd American ..
PU
2021Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63rd American..
BU
2021Legend Biotech : Announces Submission of New Drug Application to Japanese Regulatory Autho..
PU
2021Legend Biotech : Reports Third Quarter 2021 Financial Results and Recent Highlights - Form..
PU
2021Legend Biotech Reports Third Quarter 2021 Financial Results and Recent Highlights
BU
2021Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel,..
PU
1  2Volgende
Volgende evenement op LEGEND BIOTECH CORPORATION